Changes to the wholesale acquisition costs of four of the company’s insulin products will take effect in January 2024. Novo Nordisk stated in a news release that it will also bring down the price point of its unbranded biologics.
The news comes on the heels of a recent announcement from drugmaker Eli Lilly, which said March 1 it would cap insulin prices at $35 per month.
“We have been working to develop a sustainable path forward that balances patient affordability, market dynamics, and evolving policy changes,” Steve Albers, senior vice president of market access and public affairs at Novo Nordisk, said in a statement. “Novo Nordisk remains committed to ensuring patients living with diabetes can afford our insulins, a responsibility we take seriously.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.